The primary aim of the proposed center is to develop and evaluate pre-cessafion adapfive treatments for cigarette addiction. The overarching goal of this project is to evaluate the neural mechanisms that underiie pre-cessation medication effects. In a design paralleling Project 1. Clinical Trials (PD: Rose), 100 smokers will be assigned to one of four treatment arms. In all four arms, participants will confinue to smoke their usual brand of cigarettes in the two weeks prior to quitting smoking. The control (CNTRL) group will wear a placebo patch in the two weeks prior to their quit date. A second group will wear a 21 mg/d patch for the two weeks prior to the quit date (NRT-Only). A third group will switch from wearing a nicotine patch to taking varenicline in the second week (NRT??VAR). A fourth group will take bupropion SR in addition to NRT in the second week (NRT+BUP). Participants will be scanned at tiaseline and again 12 hrs after quitting smoking. During scanning, we will measure brain reactivity to smoking cues and cerebral blood fiow. Common and unique effects of pre-cessation pharmacotherapies will be identified. Based on preliminary data, we hypothesize that pre-cessation treatment will result in lower brain reactivity to smoking cues and cerebral blood flow following quitfing smoking. We also hypothesize that baseline brain funcfion will be predictive of pre- and post-quit treatment response. The proposed project builds upon the investigative team's experience and is highly integrated with the center's other projects and cores.
Cigarette smoking is the leading preventable cause of death and disability in the U.S. A new class of treatments designed to help smokers quit involves having smokers take medications before they quit smoking. This study will help us understand how the brain responds to such treatments which will guide the development of more effective treatments to help smokers quit.
|Rezvani, Amir H; Cauley, Marty C; Levin, Edward D (2014) Lorcaserin, a selective 5-HT(2C) receptor agonist, decreases alcohol intake in female alcohol preferring rats. Pharmacol Biochem Behav 125:8-14|
|Hall, Brandon J; Wells, Corinne; Allenby, Cheyenne et al. (2014) Differential effects of non-nicotine tobacco constituent compounds on nicotine self-administration in rats. Pharmacol Biochem Behav 120:103-8|
|Levin, Edward D; Hao, Ian; Burke, Dennis A et al. (2014) Effects of tobacco smoke constituents, anabasine and anatabine, on memory and attention in female rats. J Psychopharmacol 28:915-22|
|Levin, Edward D (2013) Complex relationships of nicotinic receptor actions and cognitive functions. Biochem Pharmacol 86:1145-52|
|Bough, K J; Lerman, C; Rose, J E et al. (2013) Biomarkers for smoking cessation. Clin Pharmacol Ther 93:526-38|
|Kutlu, Munir G; Burke, Dennis; Slade, Susan et al. (2013) Role of insular cortex Dýýý and Dýýý dopamine receptors in nicotine self-administration in rats. Behav Brain Res 256:273-8|
|Rezvani, Amir H; Sexton, Hannah G; Johnson, Joshua et al. (2013) Effects of caffeine on alcohol consumption and nicotine self-administration in rats. Alcohol Clin Exp Res 37:1609-17|
|Hall, F Scott; Markou, Athina; Levin, Edward D et al. (2012) Mouse models for studying genetic influences on factors determining smoking cessation success in humans. Ann N Y Acad Sci 1248:39-70|
|Levin, Edward D; Slade, Susan; Wells, Corinne et al. (2011) D-cycloserine selectively decreases nicotine self-administration in rats with low baseline levels of response. Pharmacol Biochem Behav 98:210-4|
|Levin, Edward D; Johnson, Joshua E; Slade, Susan et al. (2011) Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats. J Pharmacol Exp Ther 338:890-6|